Carbone S, et al. - This trial inspected the effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF). Findings reported that empagliflozin reduced body weight, but did not change peak VO₂. Nonetheless, patients using loop diuretics displayed an improvement. On the other hand, subjects without loop diuretics demonstrated a decrease in peak VO₂ and peak VO₂ changes appeared to be associated with the baseline daily dose of diuretics.